Randomized trial of oral cyclophosphamide and veliparib in high-grade serous ovarian, primary peritoneal, or fallopian tube cancers, or BRCA-mutant ovarian cancer

Clinical Cancer Research

Volumn 21, Issue 7, 2015, Pages 1574-1582

  Kummar, Shivaani ^a   Oza, Amit M ^b   Fleming, Gini F ^c   Sullivan, Daniel M ^d   Gandara, David R ^e   Naughton, Michael J ^f   Villalona Calero, Miguel A ^g   Morgan, Robert J ^h   Szabo, Peter M ^a   Youn, Ahrim ^a   Chen, Alice P ^a   Ji, Jiuping ⁱ   Allen, Deborah E ^a   Lih, Chih Jian ⁱ   Mehaffey, Michele G ⁱ   Walsh, William D ⁱ   McGregor, Paul M ⁱ   Steinberg, Seth M ^a   Williams, P Mickey ⁱ   Kinders, Robert J ⁱ   Conley, Barbara A ^a   Simon, Richard M ^a   Doroshow, James H ^a   more..

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g OHIO STATE UNIVERSITY   (United States)

^h CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

ⁱ FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA PROTEIN; CYCLOPHOSPHAMIDE; DNA; NIRAPARIB; NUCLEAR PROTEIN; OLAPARIB; PLATINUM DERIVATIVE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VELIPARIB; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOATING; CANCER GRADING; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEHYDRATION; DIARRHEA; DNA REPAIR; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GENE EXPRESSION; HEMATURIA; HOT FLUSH; HUMAN; HUMAN TISSUE; HYPOALBUMINEMIA; HYPOCHLOREMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LEUKOPENIA; LOW DRUG DOSE; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MENTAL DISEASE; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; OPEN STUDY; ORAL MUCOSITIS; OUTCOME ASSESSMENT; OVARY CANCER; PELVIC INFLAMMATORY DISEASE; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SEQUENCE ANALYSIS; SEROUS OVARY CANCER; SIDE EFFECT; THROMBOCYTOPENIA; TOOTH INFECTION; TREATMENT DURATION; URINARY TRACT INFECTION; UTERINE TUBE CARCINOMA; VOMITING; CLINICAL TRIAL; CYSTADENOCARCINOMA, SEROUS; DISEASE FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; GENETICS; MIDDLE AGED; MORTALITY; ORAL DRUG ADMINISTRATION; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; TUMOR SUPPRESSOR GENE;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZIMIDAZOLES; CYCLOPHOSPHAMIDE; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; FALLOPIAN TUBE NEOPLASMS; FEMALE; GENES, BRCA1; GENES, BRCA2; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS;

EID: 84927535927     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2565     Document Type: Article

References (38)

1. Kummar S, Chen A, Parchment R, Kinders R, Ji J, Tomaszewski J, et al. Advances in using PARP inhibitors to treat cancer. BMC Med 2012;10:25.
2. Sandhu SK, Yap TA, de Bono JS. Poly(ADP-ribose) polymerase inhibitors in cancer treatment: a clinical perspective. Eur J Cancer 2010;46:9-20.
3. Curtin NJ, Szabo C. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond. Mol Aspects Med 2013;34:1217-56.
4. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005;434:913-7.
5. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, et al. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123-34.
7. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
8. Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010;376:245-51.
9. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
10. Garcia AA, Hirte H, Fleming G, Yang D, Tsao-Wei DD, Roman L, et al. Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia. J Clin Oncol 2008;26:76-82.
11. Coleman M, Martin P, Ruan J, Furman R, Niesvizky R, Elstrom R, et al. Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring/refractory lymphoma: low-dose metronomic, multidrug therapy. Cancer 2008;112:2228-32.
12. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, et al. Metronomic low-dose oral cyclophosphamide andmethotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006;17:232-8.
13. Nelius T, Klatte T, de Riese W, Filleur S. Clinical outcome of patients (pts) with taxane-resistant (TR) hormone-refractory prostate cancer (HRPC) treated with second-line cyclophosphamide (CP) -based metronomic chemotherapy. J Clin Oncol 2007;25:15647.
14. Kummar S, Ji J, Morgan R, Lenz H-J, Puhalla SL, Belani CP, et al. A phase I study of veliparib in combination with metronomic cyclophosphamide in adults with refractory solid tumors and lymphomas. Clin Cancer Res 2012;18:1726-34.
15. Redon CE, Nakamura AJ, Zhang Y-W, Ji J, Bonner WM, Kinders RJ, et al. Histone g H2AX and poly(ADP-Ribose) as clinical pharmacodynamic biomarkers. Clin Cancer Res 2010;16:4532-42.
16. Wang LH, Pfister TD, Parchment RE, Kummar S, Rubinstein L, Evrard YA, et al. Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells. Clin Cancer Res 2010;16:1073-84.
17. Berry DA, Iversen ES Jr, Gudbjartsson DF, Hiller EH, Garber JE, Peshkin BN, et al. BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol 2002;20:2701-12.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
19. Simon RM, Steinberg SM, Hamilton M, Hildesheim A, Khleif S, Kwak LW, et al. Clinical trial designs for the early clinical development of therapeutic cancer vaccines. J Clin Oncol 2001;19:1848-54.
20. Freidlin B, Simon R. Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res 2005;11:7872-8.
21. Ji J, Kinders RJ, Zhang Z, Rubinstein L, Kummar S, Parchment RE, et al. Modeling pharmacodynamic response to the poly(ADP-Ribose) polymerase inhibitor ABT-888 in human peripheral blood mononuclear cells. PLoS One 2011;6:e26152.
22. Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, et al. Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 2011;71:5626-34.
23. Anderson TD. Carcinoma of the ovary. In:Fairley GH, Simister JM, editors. Cyclophosphamide (Cytoxan). Baltimore: Williams and Wilkins Co.; 1965. p. 92-7.
24. Wesolowski R, Zhao M, Geyer SM, Lustberg MB, Mrozek E, Layman RM, et al. Phase I trial of the PARP inhibitor veliparib in combination with carboplatin in metastatic breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 1074).
25. Puhalla S, Beumer JH, Pahuja S, Appleman LJ, Tawbi HA-H, Stoller RG, et al. Final results of a phase 1 study of single-agent veliparib in patients with either BRCA1/2-mutated cancer, platinum-refractory ovarian, or basal-like breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 2570).
26. Czito BG, Mulcahy MF, Schelman WR, Vaghefi H, Jameson GS, Deluca A, et al. The safety and tolerability of veliparib plus capecitabine and radiation in subjects with locally advanced rectal cancer: results of a phase 1b study. J Clin Oncol 32:5s, 2014 (suppl; abstr 3634).
27. Rodler ET, Gralow J, Kurland BF, Griffin M, Yeh R, Thompson JA, et al. Phase I: Veliparib with cisplatin and vinorelbine in advanced triple-negative breast cancer and/or BRCA mutation-associated breast cancer. J Clin Oncol 32:5s, 2014 (suppl; abstr 2569).
28. Coleman R, Sill M, Aghajanian C, Gray H, Tewari K, Rubin S, et al. Aphase II evaluation of the potent, highly selective PARP inhibitor veliparib in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who carry a germline BRCA1 or BRCA2 mutation - a Gynecologic Oncology Group study. Gynecol Oncol 2014;133(suppl 1):abstr 136:56-7.
29. LoRusso P, Ji JJ, Li J, Heilbrun LK, Shapiro G, Sausville EA, et al. Phase I study of the safety, pharmacokinetics, and pharmacodynamics of the poly (ADP-ribose) polymerase inhibitor veliparib (ABT-888) in combination with irinotecan (CPT-11) in patients with advanced solid tumors. J Clin Oncol 29: 2011 (suppl; abstr 3000).
30. Helleday T. The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol 2011;5:387-93.
31. Kedar PS, Stefanick DF, Horton JK, Wilson SH. Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts. Mol Cancer Res 2012;10:360-8.
32. Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-99.
33. Donawho CK, Luo Y, Luo Y, Penning TD, Bauch JL, Bouska JJ, et al. ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models. Clin Cancer Res 2007;13:2728-37.
34. Norquist B, Wurz KA, Pennil CC, Garcia R, Gross J, Sakai W, et al. Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas. J Clin Oncol 2011;29:3008-15.
35. Issaeva N, Thomas HD, Djurenovic T, Jaspers JE, Stoimenov I, Kyle S, et al. 6-Thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 2010;70:6268-76.
36. Lord CJ, Ashworth A. Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 2013;19:1381-8.
37. Lutsiak ME, Semnani RT, De Pascalis R, Kashmiri SV, Schlom J, Sabzevari H. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 2005;105:2862-8.
38. Forbes SA, Bindal N, Bamford S, Cole C, Kok CY, Beare D, et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res 2011;39:D945-50.